Navigation Links
TGen-Scottsdale Healthcare clinical trial finds new class of cancer drugs safe and effective
Date:4/9/2013

SCOTTSDALE, Ariz. April 9, 2013 The safety and preliminary efficacy of a new class of tumor fighting drugs were reported today by Scottsdale Healthcare's Virginia G. Piper Cancer Center Clinical Trials and the Translational Genomics Research Institute (TGen).

Early results from the phase I, first in-human study of an RNA interface (RNAi) drug were announced during the American Association for Cancer Research (AACR) Annual Meeting 2013, April 6-10, in Washington, D.C. The drug, TKM-080301 (also known as TKM-PLK1) is being developed by Tekmira Pharmaceuticals Corporation.

The study was conducted at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership with TGen. It found that the RNAi drug acts by silencing the PLK1 gene involved in tumor growth and can be safely administered in humans. Most patients tolerated the drug well; some showed therapeutic benefit.

"RNAi therapies are a unique approach to cancer treatment as they have the potential to 'turn off' the genes' coding for proteins involved in cancer cell division," said Dr. Ramesh K. Ramanathan, Medical Director of Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare and deputy director of the Clinical Translational Research Division of TGen. "Using a lipid nanoparticle, the RNAi drug can be delivered to a cancer cell to block the expression of specific proteins involved in tumor growth."

TKM-080301 targets a specific gene called polo-like kinase 1 (PLK1), which codes for a protein involved in tumor cell growth. Prior research has shown that high levels of PLK1 are present in many types of cancer, including many of the more aggressive forms.

"Our preclinical results have shown that by decreasing PLK1 levels in cancer cells, we can stop tumor growth and kill the cancer cells," Dr. Ramanathan said.

He and his colleagues have been enrolling patients with advanced solid tumors or lymphoma into the ongo
'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Weill Cornell Medical College establishes Center for Healthcare Informatics and Policy
2. Coral Calcium Company Announces New Offer Amidst Supreme Court Healthcare Decisions
3. Healthcare researchers recognized at SingHealth Duke-NUS Scientific Congress 2012
4. Daily disinfection of isolation rooms reduces contamination of healthcare workers hands
5. Health inequalities could be reduced by more effective healthcare, says new study
6. Healthcare ethics consultants share lessons learned
7. Kessler Foundation stroke expert receives $145,000 grant from Healthcare Foundation of New Jersey
8. Social environmental factors affect rehospitalization risk in home healthcare patients
9. TGen, Scottsdale Healthcare lead worldwide study of new drug for patients with pancreatic cancer
10. CWRU dental and nursing students collaborate for one-stop healthcare
11. University Hospitals & Philips Healthcare to showcase imaging technology at Cleveland Medical Mart
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... -- For patients infected with both HIV and hepatitis ... viruses, a small study suggests. Researchers said doctors ... people with the two diseases. "The findings ... important role in the management of individuals with [hepatitis ... Sherman, a professor of medicine at the University of ...
(Date:7/23/2014)... Cancer is a disease of the genome resulting from ... from our parents strong or weak predispositions to developing ... new mutations in our cells throughout our lifetime. Although ... a long time, researchers were not able to measure ... now. A team of geneticists from the University of ...
(Date:7/23/2014)... MI (PRWEB) July 23, 2014 Ticket ... Madrid vs. Manchester United tickets at Michigan Stadium . ... International Champions Cup will be held at the Big House ... of Michigan Wolverines, will be home to a game between ... from La Liga. The game will be held on August ...
(Date:7/23/2014)... NJ (PRWEB) July 23, 2014 CarePoint ... the first hospital in New Jersey to receive the ... advanced robotics platform in the da Vinci series. This ... a profound step forward in innovation. The intuitive da ... across a wide spectrum of minimally invasive and complex ...
(Date:7/23/2014)... This report defines and segments the "EHV ... Middle East & Africa, and Americas) - Global Trends ... analysis and forecasts of the global revenue. The global ... $10 billion in 2014 to nearly $14 billion by ... browse 49 Market Tables and 10 Figures Spread Through ...
Breaking Medicine News(10 mins):Health News:HIV Meds May Also Help Control Hepatitis C, Study Finds 2Health News:Genetics of cancer: Non-coding DNA can finally be decoded 2Health News:Real Madrid vs. Manchester United Tickets Ann Arbor: Ticket Down Slashes Ticket Prices for ManU vs. Real Madrid Guinness International Champions Cup Tickets 2Health News:Real Madrid vs. Manchester United Tickets Ann Arbor: Ticket Down Slashes Ticket Prices for ManU vs. Real Madrid Guinness International Champions Cup Tickets 3Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 2Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 3Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 4Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 2Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 3Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 4
... Mass., Oct. 30 Repligen Corporation,(Nasdaq: RGEN ) ... Walter C. Herlihy, Ph.D., will host a conference call,and ... EST, to report,second quarter fiscal year 2009 financial results ... This call is being webcast by Thomson/CCBN and can ...
... Prices, According To New Data ... from Arlington Medical Resources, MALVERN, Penn., Oct. 30 ... the pharmaceutical and,diagnostic imaging industries, finds that echinocandins show growth in ... courses,in the January - June 2008 time period compared to 9 ...
... Visit Washington D.C. to Rally Residents to Eat Right, Move ... More and Milk Their ... by,the ups and downs of different fad diets -- which seem to ... success has been,slim. Two out of three Americans -- including 22% of ...
... Mid-Atlantic Region, ATLANTA, Oct. 30 AmeriCare ( ... the opening of its,latest franchises serving Howard, Montgomery, and ... states in the union, Maryland is in the,top 20 ... Marylanders is over the,age of 60. AmeriCare of Maryland ...
... MIAMI, Oct. 30 Physicians Healthcare,Management Group, Inc. (Phyhealth) ... in partnership with physicians,today announced that its board of ... to 5% of the Company,s outstanding Common Stock., ... at the market price.,The purchases will be made at ...
... MED ) announced today that it will release third quarter ... 30, 2008 on,Thursday, November 6, 2008. The Company will hold ... Thursday, November 6, at 11:00 a.m. ET., Interested parties ... or can listen via a live Internet web cast, which ...
Cached Medicine News:Health News:Repligen Announces Conference Call of Second Quarter Fiscal Year 2009 Results Thursday, November 6th, 10:00 a.m. EST 2Health News:Repligen Announces Conference Call of Second Quarter Fiscal Year 2009 Results Thursday, November 6th, 10:00 a.m. EST 3Health News:Echinocandins Show Growth Among All Antifungal Classes 2Health News:Echinocandins Show Growth Among All Antifungal Classes 3Health News:Message to Washington D.C. Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Washington D.C. Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Caregiving Company AmeriCare Adds Franchise in Maryland 2Health News:Phyhealth Announces Stock Buyback Program 2Health News:Phyhealth Announces Stock Buyback Program 3Health News:Medifast, Inc. to Announce Third Quarter of Fiscal Year 2008 Financial Results on Thursday, November 6, 2008 2
(Date:7/23/2014)... Calif., July 23, 2014  Varian Medical Systems (NYSE: ... of $1.02 per diluted share in the third quarter ... by about $0.06 per diluted share due to an ... of Varian,s existing equity investment in Augmenix, a privately-held ... revenues totaled $748 million for the third quarter of ...
(Date:7/23/2014)... , July 23, 2014 UBM Medica ... – a new online community and information resource for ... manage and treat their patients with neurological disorders ... with an aging population, necessitates greater access to dedicated ...  Key statistics on neurological conditions include: , ...
(Date:7/23/2014)... , July 23, 2014 The Board ... ), a leading provider of clinical trial imaging solutions, ... has been named president and chief executive officer, effective ... in August 2013 and has held the positions of ... 2013. Dr. Charles E. Phelps , ...
Breaking Medicine Technology:Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 3Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 4Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 6Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 7Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 8Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 9Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 10UBM Medica US Launches NeurologyTimes.com 2UBM Medica US Launches NeurologyTimes.com 3Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 2Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 3Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 4
... , HOLMDEL, N.J., Nov. 24 Sparta Systems, Inc., ... enterprise quality and compliance solutions, today announced that SSL International ... company for globally recognized brands such as Durex and Scholl, ... The company is now leveraging the TrackWise system to harmonize ...
... , MISSISSAUGA, Ontario, Nov. 24 CardioGenics Holdings Inc. (OTC ... the immunoassay segment of the IVD testing market, reports that ... phase of the commercialization of CardioGenics, proprietary silver coated paramagnetic ... Chimie that was executed earlier this year, CardioGenics supplied Merck ...
Cached Medicine Technology:SSL International plc Embraces TrackWise(R) Software for Global Quality and Compliance Efforts 2SSL International plc Embraces TrackWise(R) Software for Global Quality and Compliance Efforts 3CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 2CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 3
... drive system which eliminates many of ... out. There are no motor brushes, ... drive belts - resulting in a ... carry weights up to 400 pounds. ...
... The Quinton Q-Stress Cardiac Stress ... baseline wander and muscle artifact ... second to provide the highest ... Leads can be displayed in ...
... ECT WS 2000 is designed to monitor, ... cardiovascular provocative tests, (stress-testing). The system can organize ... and provide them for a quick review and ... ,The recorded ECG is transmitted via a small ...
... compact BioStress 2000 is a software driven, ... testing system. The BioStress 2000 program is ... viewing, permanent ECG strorage and retrieval and ... printer. BioStress 2000 allows a wide range ...
Medicine Products: